Abstract | BACKGROUND AND AIMS: PATIENTS AND METHOD: From January 2007 to July 2012, a quantitative assessment of serum MUC5AC was performed with enzyme-linked immunoassay in a total of 88 subjects. Clinical and biochemical data (including CEA and Ca 19-9) of 49 patients with BTC were compared with a control population that included 23 patients with benign biliary disease (BBD) and 16 healthy control subjects (HCS). RESULTS: Serum MUC5AC was greater in BTC patients (mean 17.93 ± 10.39 ng/mL) compared with BBD (mean 5.95 ± 5.39 ng/mL; P < .01) and HCS (mean 2.74 ± 1.35 ng/mL) (P < .01). Multivariate analysis showed that MUC5AC was related with the presence of BTC compared with Ca 19-9 and CEA: P < .01, P = .080, and P = .463, respectively. In the BTC group, serum MUC5AC ≥ 14 ng/mL was associated with lymph-node metastasis (P = .050) and American Joint Committee on Cancer and International Union for Cancer Control stage IVb disease (P = .047). Moreover, in patients who underwent operation with curative intent, serum MUC5AC ≥ 14 ng/mL was related to a worse prognosis compared with patients with lesser levels, with 3-year survival rates of 21.5% and 59.3%, respectively (P = .039). CONCLUSION: MUC5AC could be proposed as new serum marker for BTC. Moreover, the quantitative assessment of serum MUC5AC could be related to tumor stage and long-term survival in patients with BTC undergoing operation with curative intent.
|
Authors | Andrea Ruzzenente, Calogero Iacono, Simone Conci, Francesca Bertuzzo, Gianluca Salvagno, Orazio Ruzzenente, Tommaso Campagnaro, Alessandro Valdegamberi, Silvia Pachera, Fabio Bagante, Alfredo Guglielmi |
Journal | Surgery
(Surgery)
Vol. 155
Issue 4
Pg. 633-9
(Apr 2014)
ISSN: 1532-7361 [Electronic] United States |
PMID | 24468034
(Publication Type: Journal Article)
|
Copyright | Copyright © 2014 Mosby, Inc. All rights reserved. |
Chemical References |
- Biomarkers, Tumor
- MUC5AC protein, human
- Mucin 5AC
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Biliary Tract Neoplasms
(blood, diagnosis, mortality, pathology)
- Biomarkers, Tumor
(blood)
- Case-Control Studies
- Cholangiocarcinoma
(blood, diagnosis, mortality, pathology)
- Female
- Humans
- Male
- Middle Aged
- Mucin 5AC
(blood)
- Multivariate Analysis
- Neoplasm Staging
- Prognosis
- Prospective Studies
- Retrospective Studies
- Survival Rate
|